Acute intermittent porphyria: a diagnostic challenge.

Karol Bigosiński(Medical University of Lublin), Marek Hus(Medical University of Lublin), Aneta Szudy‐Szczyrek(Medical University of Lublin), Maciej Dubaj(Medical University of Lublin)

Acta Haematologica Polonica

August 31, 2024

10.5603/ahp.101063

Cited by 4

Related Papers

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

|New England Journal of Medicine|2024|162

Thalidomide treatment of resistant or relapsed multiple myeloma patients.

|PubMed|2001|85

Therapy‐related peripheral neuropathy in multiple myeloma patients

|Hematological Oncology|2014|70

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis

|Leukemia|2022|63

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma

|Annals of Hematology|2011|62